Dr. Oehler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-667-1340
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2000 - 2003- University of WashingtonResidency, Internal Medicine, 1997 - 2000
Case Western Reserve University School of MedicineClass of 1997
Certifications & Licensure
WA State Medical License 1999 - 2027- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
- Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Start of enrollment: 2020 Jan 09
- A Study of TAS1440 With ATRA in Subjects With r/r AML Start of enrollment: 2020 Mar 15
Publications & Presentations
PubMed
- 1 citationsOlverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.Elias Jabbour, Vivian G Oehler, Paul B Koller, Omer Jamy, Elza Lomaia
JAMA Oncology. 2025-01-01 - Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and When.Vivian G Oehler, Ivan J Huang, Chloe Siu, Miryoung Kim, Jessie Signorelli
Journal of the National Comprehensive Cancer Network. 2024-11-01 - Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial.Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R Kelly, Vivian G Oehler
Leukemia. 2024-10-01
Journal Articles
- Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica
Abstracts/Posters
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Vivian G. Oehler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...Vivian G. Oehler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)Vivian G. Oehler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- High Throughput Drug Screening of Leukemia Stem Cells Reveals Resistance to Standard Therapies and Sensitivity to Other Agents in Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Dr. Glenda Gray Among Time Magazine’s ‘100 Most Influential’April 20th, 2017
Grant Support
- Integrating Diagnostics With Therapeutic Strategies In Chronic Myeloid LeukemiaNational Cancer Institute2009–2011
- Examination Of Imatinib Mesylate Resistance In CMLNational Cancer Institute2004–2008
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
